HemaQuest Pharmaceuticals, Inc.: Series B $13M

Posted in I - Series B, Q - 1Q11, R - WEST, X - Beta Thalassemia, X - Hemoglobin, X - Sickle Cell, XX - CA

HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as [...]

Jul

2011

Sangart, Inc.: Series G $50M

Posted in I - Series G, Q - 2Q11, R - WEST, X - Hemoglobin, XX - CA

Sangart (Sa Diego, CA) a clinical-stage biopharmaceutical focused on perfusion of ischemic tissue and targeted oxygen delivery in the capillaries, closed a $50M Series G financing. Participants include Leucadia.

Apr

2010

HemaQuest Pharmaceuticals, Inc. Series B $12M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Antiviral, X - EBV, X - Hemoglobin, X - HIV, X - HPV, X - Sickle Cell, XX - MA

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Mar

2009

Sangart, Inc.: Series F $50M

Posted in I - Series F, Q - 1Q09, R - WEST, X - Hemoglobin, XX - CA

Sangart (San Diego, CA) a clinical-stage artificial blood substitute focused on targeting oxygen delivery to tissues that are insufficiently oxygenated, closed a $50M Series F financing, the final tranche of the $100M round. Participants include Leucadia National who owns approximately 92% of the company after investing approximately $146.2M since 2003.

to top of page...